II. Indications
- Methicillin-Resistant Staphylococcus aureus (MRSA)
- Complicated Skin Infections
- Do not use for Pneumonia
- Poorly penetrates lung
- Inactivated by surfactant
III. Mechanism
- Cyclic Lipopeptide
- Depolarizes Bacterial cell membranes
IV. Preparations
- Intravenous daily dosing
V. Dosing: Adults
- Daptomycin 4 mg/kg in NS over 30 minutes once daily
VII. Monitoring
- Obtain serum CPK level weekly while on Daptomycin
Images: Related links to external sites (from Bing)
Related Studies
| Definition (MSH) | A cyclic lipopeptide antibiotic that inhibits GRAM-POSITIVE BACTERIA. |
| Definition (NCI) | A semi-synthetic cyclic lipopeptide antibiotic isolated form the bacterium Streptomyces roseosporus with broad-spectrum antibiotic activity against Gram-positive bacteria. Daptomycin has a distinct mechanism of action, in which it binds to bacterial membrane and causes rapid depolarization of the cell membrane due to calcium-dependant potassium efflux; the loss of membrane potential leads to inhibition of DNA, RNA and protein synthesis, resulting in bacterial cell death. This agent does not penetrate the outer membrane of gram-negative bacteria. |
| Definition (NCI_NCI-GLOSS) | A drug used to treat certain bacterial skin and bloodstream infections in adults. Cubicin is also being studied in the treatment of fever and neutropenia (an abnormal decrease in the number of neutrophils, a type of white blood cell) in patients with cancer. It is a type of antibiotic. |
| Definition (PDQ) | A semi-synthetic cyclic lipopeptide antibiotic isolated form the bacterium Streptomyces roseosporus with broad-spectrum anitbiotic activity against Gram-positive bacteria. Daptomycin has a distinct mechanism of action, in which it binds to bacterial membrane and causes rapid depolarization of the cell membrane due to calcium-dependant potassium efflux; the loss of membrane potential leads to inhibition of DNA, RNA and protein synthesis, resulting in bacterial cell death. This agent does not penetrate the outer membrane of gram-negative bacteria. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=469015&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=469015&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C47470" NCI Thesaurus) |
| Concepts | Antibiotic (T195) , Amino Acid, Peptide, or Protein (T116) |
| MSH | D017576 |
| SnomedCT | 406438001, 406439009 |
| LNC | LP33354-9, MTHU016673 |
| English | Daptomycin, Deptomycin, N-Decanoyl-L-tryptophyl-L-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-threo-3-methyl-L-glutamyl-3-anthraniloyl-L-alanine epsilon1-lactone, N-decanoyl-L-tryptophyl-L-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-threo-3-methyl-L-glutamyl-3-anthraniloyl-L-alanine-epsilon1-lactone, daptomycin (medication), Daptomycin [Chemical/Ingredient], DAPTOmycin, daptomycin, Daptomycin (product), Daptomycin (substance), DAPTOMYCIN |
| Swedish | Daptomycin |
| Czech | daptomycin |
| Finnish | Daptomysiini |
| Russian | DAPTOMITSIN, ДАПТОМИЦИН |
| Japanese | ダプトマイシン |
| Polish | Daptomycyna |
| Spanish | daptomicina (producto), daptomicina (sustancia), daptomicina, Daptomicina |
| French | Daptomycine |
| German | Daptomycin |
| Italian | Daptomicina |
| Portuguese | Daptomicina |
Ontology: Cyclic lipopeptide antibiotic (C1320334)
| Concepts | Antibiotic (T195) , Organic Chemical (T109) |
| SnomedCT | 406437006, 406440006 |
| Spanish | lipopéptidos cíclicos, lipopéptidos cíclicos (producto), lipopéptidos cíclicos (sustancia), antibiótico lipopeptídico cíclico, antibiótico lipopeptídico cíclico (sustancia), antibiótico lipopeptídico cíclico (producto), antibióticos lipopéptidos cíclicos (producto), ántibióticos lipopéptidos cíclicos (sustancia), antibióticos lipopéptidos cíclicos, ántibióticos lipopéptidos cíclicos |
| English | Cyclic lipopeptides, Cyclic lipopeptide antibiotic (product), Cyclic lipopeptide antibiotic (substance), Cyclic lipopeptide antibiotic, Cyclic lipopeptides (product), Cyclic lipopeptides (substance) |
Ontology: Cubicin (C1330170)
| Concepts | Amino Acid, Peptide, or Protein (T116) , Antibiotic (T195) |
| MSH | D017576 |
| English | Cubist Brand of Injectable Daptomycin, Cubicin |
